医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MTTI receives expanded patent approval for 99mTc-Duramycin technology to target programmed cell death

2015年05月16日 AM02:29
このエントリーをはてなブックマークに追加


 

WEST CHESTER, Pa.

Molecular Targeting Technologies, Inc. (MTTI) announces today that the patent which it has exclusively licensed from the Medical College of Wisconsin (MCW), was granted by the patent office of the People’s Republic of China. The Chinese patent, along with several U.S. patents, cover a novel radiopharmaceutical molecule, which can be used for targeting dead and dying cells associated with cancer, inflammation, and cardiovascular diseases.

“We are excited about MTTI’s aggressive plan to develop the compounds encompassed by this patent into radiopharmaceuticals to benefit clinicians and their patients,” said Jim Antczak, Ph.D., a licensing manager in MCW’s Office of Technology Development.

In commenting on one of the potential uses of this technology, Professor Jagat Narula, Associate Dean of Global Health of Mount Sinai Medical School said, “Onset of cardiac toxicity during chemotherapy is routinely monitored by measurement of left ventricle ejection fraction (LVEF). Unfortunately, by the time a decrease in LVEF is detected the cardiac damage has already occurred. 99mTc-Duramycin has the potential to detect cardiac injury before left ventricular dysfunction has occurred, providing the opportunity for timely clinical intervention. Successful development of 99mTc-Duramycin would be of great clinical significance and fulfill a significant unmet medical need.”

Chris Pak, President and CEO of MTTI said, “We are encouraged by the issuing of the patents in China as well as in U.S. Imaging efficacy of 99mTc-Duramycin has been demonstrated in several animal models. Most importantly, this technology can be used to target unmet medical needs in a variety of diseases.”

Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company primarily focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases. MTTI has licensed and is developing two major technology platforms to provide: (i) novel small molecule drug conjugate (SMDC) cancer therapeutic, and (ii) in vivo imaging agents. Please visit our website: www.mtarget.com for more information.

The Medical College of Wisconsin (MCW) is Wisconsin’s only private medical school and health sciences graduate school. Founded in 1893, it is dedicated to leadership and excellence in education, patient care, research and service. Please visit MCW’s website: www.mcw.edu for more information.

CONTACT

MTTI
Chris Pak
610-738-7938
cpak@mtarget.com
or
MCW
Maureen
Mack, Director of Media Relations
Tel: 414-955-4744
Cell:
414-750-5266
mmack@mcw.edu

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment